Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
SymbolNYSE:DPLO
CUSIPN/A
Phone888-720-4450
Debt
Debt-to-Equity Ratio0.59
Current Ratio0.88
Quick Ratio0.57
Price-To-Earnings
Trailing P/E Ratio32.86
Forward P/E Ratio30.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.49 billion
Price / Sales0.46
Cash Flow$1.9450 per share
Price / Cash14.19
Book Value$10.88 per share
Price / Book2.54
Profitability
EPS (Most Recent Fiscal Year)$0.84
Net Income$15.51 million
Net Margins0.23%
Return on Equity8.80%
Return on Assets4.07%
Miscellaneous
Employees2,419
Outstanding Shares74,130,000
Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions
What is Diplomat Pharmacy's stock symbol?
Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."
How were Diplomat Pharmacy's earnings last quarter?
Diplomat Pharmacy Inc (NYSE:DPLO) released its earnings results on Monday, May, 7th. The company reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.01. The firm earned $1.34 billion during the quarter, compared to analysts' expectations of $1.28 billion. Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The business's quarterly revenue was up 24.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.19 earnings per share. View Diplomat Pharmacy's Earnings History.
When is Diplomat Pharmacy's next earnings date?
What guidance has Diplomat Pharmacy issued on next quarter's earnings?
Diplomat Pharmacy issued an update on its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share guidance of $0.87-$0.97 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.92. The company issued revenue guidance of $5.5-$5.9 billion, compared to the consensus revenue estimate of $5.44 billion.
What price target have analysts set for DPLO?
10 equities research analysts have issued 12-month price objectives for Diplomat Pharmacy's stock. Their forecasts range from $18.00 to $35.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $27.2222 in the next year. View Analyst Ratings for Diplomat Pharmacy.
Who are some of Diplomat Pharmacy's key competitors?
Who are Diplomat Pharmacy's key executives?
Diplomat Pharmacy's management team includes the folowing people:
- Mr. Joel Saban, Pres (Age 50)
- Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 66)
- Mr. Atul Kavthekar, CFO & Treasurer
- Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 60)
- Mr. Brian Thomas Griffin, CEO & Chairman (Age 59)
Has Diplomat Pharmacy been receiving favorable news coverage?
News articles about DPLO stock have been trending positive recently, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a news sentiment score of 0.34 on Accern's scale. They also assigned headlines about the company an impact score of 45.44 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Diplomat Pharmacy's major shareholders?
Diplomat Pharmacy's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.79%), Frontier Capital Management Co. LLC (5.29%), Dimensional Fund Advisors LP (1.75%), Northern Trust Corp (1.66%), GW&K Investment Management LLC (1.38%) and Cambridge Investment Research Advisors Inc. (1.36%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.
Which institutional investors are selling Diplomat Pharmacy stock?
DPLO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Cortina Asset Management LLC, BlackRock Inc., Cambridge Investment Research Advisors Inc., JPMorgan Chase & Co., Citigroup Inc., Broadview Advisors LLC and Granite Investment Partners LLC. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.
Which institutional investors are buying Diplomat Pharmacy stock?
DPLO stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redwood Investments LLC, Matarin Capital Management LLC, Hood River Capital Management LLC, Palisade Capital Management LLC NJ, Mackay Shields LLC, Frontier Capital Management Co. LLC and State of Wisconsin Investment Board. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.
How do I buy shares of Diplomat Pharmacy?
Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diplomat Pharmacy's stock price today?
One share of DPLO stock can currently be purchased for approximately $27.60.
How big of a company is Diplomat Pharmacy?
Diplomat Pharmacy has a market capitalization of $1.93 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.
How can I contact Diplomat Pharmacy?
Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]
MarketBeat Community Rating for Diplomat Pharmacy (DPLO)
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
